

Overview of non-Hodgkin[apos]s lymphoma: Biology, s

Seminars in Oncology

30, 3-9

DOI: [10.1053/sonc.2003.23797](https://doi.org/10.1053/sonc.2003.23797)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Small cell lung cancer: from molecular biology to novel therapeutics. <i>Journal of Experimental Therapeutics and Oncology</i> , 2003, 3, 305-318.	0.5	14
2	Limited-disease small-cell lung cancer. <i>Journal of Surgical Oncology</i> , 2003, 21, 156-163.	1.4	6
3	A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). <i>British Journal of Cancer</i> , 2003, 89, 1766-1775.	2.9	71
4	Results of a Phase II Multicenter Trial of Pentostatin and Rituximab in Patients with Low-Grade B-Cell Non-Hodgkin's Lymphoma: An Effective and Minimally Toxic Regimen. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 169-175.	2.1	19
5	Gene Expression Profiling as a Diagnostic and Prognostic Tool in B-Cell Non-Hodgkin's Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2003, 4, 149-151.	2.1	0
6	Increased butyrate formation in the pig colon by feeding raw potato starch leads to a reduction of colonocyte apoptosis and a shift to the stem cell compartment. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 1400-1405.	1.5	96
8	Genotypic analysis of esophageal squamous cell carcinoma by molecular cytogenetics and real-time quantitative polymerase chain reaction. <i>International Journal of Oncology</i> , 2003, 23, 871.	1.4	12
9	Diffuse large B-cell lymphoma presenting as a sacral tumor. <i>Neurosurgical Focus</i> , 2003, 15, 1-5.	1.0	11
10	Overview of targeted therapies for cancer. <i>American Journal of Health-System Pharmacy</i> , 2003, 60, S4-S10.	0.5	24
11	Palliative Chemotherapy And/Or Radiotherapy for Pancreatic Cancer: What Can Be Expected?. , 0, , 465-471.		0
13	Molecular Biology of Cervical and Vulvar Carcinoma. , 2004, , 65-78.		3
14	Selective Tyrosine Hyperphosphorylation of Cytoskeletal and Stress Proteins in Primary Human Breast Cancers. <i>Clinical Cancer Research</i> , 2004, 10, 3980-3987.	3.2	37
15	Synergistic Interaction between Sphingomyelin and Gemcitabine Potentiates Ceramide-Mediated Apoptosis in Pancreatic Cancer. <i>Cancer Research</i> , 2004, 64, 8405-8410.	0.4	62
16	Treatment of SLE with Anti-CD20 Monoclonal Antibody. , 2004, 8, 193-205.		39
17	Targeting of Radio-Isotopes for Cancer Therapy. <i>Cancer Biology and Therapy</i> , 2004, 3, 361-370.	1.5	54
18	Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR). <i>Cancer Research</i> , 2004, 64, 5355-5362.	0.4	369
19	Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis. <i>Cancer Research</i> , 2004, 64, 4585-4592.	0.4	184
20	Denileukin Diftitox as Novel Targeted Therapy in Non-Hodgkin's Lymphoma. <i>Clinical Journal of Oncology Nursing</i> , 2004, 8, 169-174.	0.3	7

#	ARTICLE	IF	CITATIONS
21	The Biology of CD20 and Its Potential as a Target for mAb Therapy. , 2004, 8, 140-174.		297
22	Clinical experience with fludarabine in indolent non-Hodgkin's lymphoma. The Hematology Journal, 2004, 5, S38-S49.	2.0	6
23	Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. The Hematology Journal, 2004, 5, 467-471.	2.0	23
24	Cetuximab (Erbix) - an emerging targeted therapy for epidermal growth factor receptor-expressing tumours. International Journal of Clinical Practice, 2004, 58, 970-976.	0.8	30
25	Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatric Transplantation, 2004, 8, 535-542.	0.5	161
26	p53-independent anti-tumor effects of the nitrogen-containing bisphosphonate zoledronic acid. Cancer Science, 2004, 95, 186-192.	1.7	37
27	Activity of single-agent melphalan 220â€“300â€“mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplantation, 2004, 33, 781-787.	1.3	21
28	Epidermal growth factor receptor tyrosine kinase inhibitors. British Journal of Cancer, 2004, 90, 2250-2255.	2.9	103
29	Plasmapheresis, CMV Hyperimmune Globulin, and Anti-CD20 Allow ABO-Incompatible Renal Transplantation Without Splenectomy. American Journal of Transplantation, 2004, 4, 1315-1322.	2.6	267
30	Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma. Seminars in Oncology, 2004, 31, 2-6.	0.8	11
31	Functional Regulation of Human Neutrophil Fc Î³ Receptors. Immunologic Research, 2004, 29, 219-230.	1.3	59
32	Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatric Nephrology, 2004, 19, 794-797.	0.9	170
33	Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer, 2004, 11, 38-41.	1.3	25
34	Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis and Rheumatism, 2004, 50, 3580-3590.	6.7	426
35	Activity of interferon-? and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer, 2004, 100, 574-580.	2.0	27
36	Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer, 2004, 100, 2592-2597.	2.0	59
37	Cytokines in pancreatic carcinoma. Cancer, 2004, 101, 2727-2736.	2.0	273
38	A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1494-1501.	0.4	46

#	ARTICLE	IF	CITATIONS
40	Pharmacogenetics of neoplastic diseases: new trends. <i>Pharmacological Research</i> , 2004, 49, 331-342.	3.1	21
41	Development of Rationally Designed, Target-Based Agents for the Treatment of Advanced Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 4, 107-123.	1.0	4
44	Radiation therapy and chemotherapy in the treatment of limited-disease small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 343-353.	0.9	1
45	Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. <i>Nuclear Medicine and Biology</i> , 2004, 31, 469-476.	0.3	67
46	Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. <i>Journal of Hepatology</i> , 2004, 41, 808-814.	1.8	117
47	Sustained activation of epidermal growth factor receptor in cholangiocarcinoma: a potent therapeutic target?. <i>Journal of Hepatology</i> , 2004, 41, 859-861.	1.8	6
48	Molecular therapy in pancreatic adenocarcinoma. <i>Lancet Oncology</i> , The, 2004, 5, 541-549.	5.1	69
51	Characterization of clonogenic multiple myeloma cells. <i>Blood</i> , 2004, 103, 2332-2336.	0.6	738
52	A new anti-idiotypic antibody capable of binding rituximab on the surface of lymphoma cells. <i>Blood</i> , 2004, 104, 2540-2542.	0.6	44
53	Clinical and Pathological Features of Posttransplantation Lymphoproliferative Disorders Presenting With Skin Involvement in 4 Patients. <i>Archives of Dermatology</i> , 2004, 140, 1140-6.	1.7	43
54	Targeted Therapy for the Treatment of Advanced Non-small Cell Lung Cancer. <i>Chest</i> , 2005, 128, 3975-3984.	0.4	98
55	Neoplasms of the Lung, Pleura and Chest Wall. , 2005, , 165-183.		0
56	A Prognostic Model for HIV Seroconversion Among Injection Drug Users as a Tool for Stratification in Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 489-495.	0.9	21
57	Cyclooxygenase-2 (COX-2) Levels Before and After Chemotherapy: A Study in Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 560-564.	0.6	12
58	EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2005, 29, 633-639.	2.1	229
59	Bcl-2 inhibitors potentiate the cytotoxic effects of radiation in Bcl-2 overexpressing radioresistant tumor cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 517-528.	0.4	40
60	Gamma camera scans and pretreatment tumor volumes as predictors of response and progression after Y-90 anti-CD20 radioimmunotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 194-201.	0.4	28
61	Identification of peptides that bind to irradiated pancreatic tumor cells. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 62, 1497-1503.	0.4	10

#	ARTICLE	IF	CITATIONS
62	The Safety of Full-Dose Chemotherapy with Secondary Prophylactic Granulocyte Colony Stimulating Factor (G-CSF) Following a Prior Cycle with Febrile Neutropenia. <i>Medical Oncology</i> , 2005, 22, 229-232.	1.2	12
63	Cholesterol depletion inhibits src family kinase-dependent calcium mobilization and apoptosis induced by rituximab crosslinking. <i>Immunology</i> , 2005, 116, 223-232.	2.0	50
64	Continuing challenges in childhood non-Hodgkin's lymphoma. <i>British Journal of Haematology</i> , 2005, 130, 480-488.	1.2	22
65	Selective inhibition of TNF- α -induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib. <i>British Journal of Cancer</i> , 2005, 92, 1690-1695.	2.9	28
66	T cells armed with anti-CD3 $\tilde{\text{A}}$ - anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro. <i>Experimental Hematology</i> , 2005, 33, 452-459.	0.2	57
67	Redefining Bronchioloalveolar Carcinoma. <i>Seminars in Oncology</i> , 2005, 32, 329-335.	0.8	25
68	PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis. <i>European Journal of Haematology</i> , 2005, 74, 66-69.	1.1	52
69	Folate receptor-targeted immunotherapy: Induction of humoral and cellular immunity against hapten-decorated cancer cells. <i>International Journal of Cancer</i> , 2005, 116, 710-719.	2.3	71
71	Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 487-494.	1.2	28
72	Clinical experience with monoclonal antibodies to epidermal growth factor receptor. <i>Current Oncology Reports</i> , 2005, 7, 96-103.	1.8	21
73	Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 650-658.	1.9	111
74	Anti-B cell therapy (Rituximab) in the treatment of autoimmune diseases. <i>Lupus</i> , 2005, 14, 210-214.	0.8	71
75	Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1962-1971.	1.9	27
76	Trimodal Cancer Treatment: Beneficial Effects of Combined Antiangiogenesis, Radiation, and Chemotherapy. <i>Cancer Research</i> , 2005, 65, 3643-3655.	0.4	171
77	Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva $\hat{\text{A}}$) and Gefitinib (Iressa $\hat{\text{A}}$). <i>Oncologist</i> , 2005, 10, 579-589.	1.9	107
78	SKI-606, a Src/Abl Inhibitor with In vivo Activity in Colon Tumor Xenograft Models. <i>Cancer Research</i> , 2005, 65, 5358-5364.	0.4	141
79	Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas. <i>Leukemia and Lymphoma</i> , 2005, 46, 225-231.	0.6	41
80	Differential Immunoscreening Identifies a Glycosylation Variant of the Epidermal Growth Factor Receptor in ME-180 Cervical Carcinoma Cells. <i>Hybridoma</i> , 2005, 24, 225-230.	0.5	2

#	ARTICLE	IF	CITATIONS
81	Lack of EGF receptor contributes to drug sensitivity of human germline cells. <i>British Journal of Cancer</i> , 2005, 92, 334-341.	2.9	11
82	Epidermal Growth Factor Receptor Inhibitors: A Moving Target?. <i>Clinical Cancer Research</i> , 2005, 11, 7203-7205.	3.2	16
83	The Clinical Use of Tumor Markers in Select Cancers: Are You Confident Enough to Discuss Them With Your Patients?. <i>Oncology Nursing Forum</i> , 2005, 32, 1013-1025.	0.5	4
84	Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. <i>Annals of Oncology</i> , 2005, 16, 1646-1653.	0.6	43
85	Conditional EGFR Promotes Cell Cycle Progression and Prevention of Apoptosis in the Absence of Autocrine Cytokines. <i>Cell Cycle</i> , 2005, 4, 822-830.	1.3	27
86	Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 435-442.	1.9	111
87	Effects of Endogenous Epidermal Growth Factor Receptor Signaling on DNA Synthesis and ERK Activation in a Cytokine-Dependent Hematopoietic Cell Line. <i>Cell Cycle</i> , 2005, 4, 818-821.	1.3	11
88	Adverse Drug Interactions and Reactions in Dermatology: Current Issues of Clinical Relevance. <i>Dermatologic Clinics</i> , 2005, 23, 335-342.	1.0	13
89	HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. <i>Blood</i> , 2005, 106, 59-66.	0.6	210
90	Tolerability and safety of rituximab (MabThera®). <i>Cancer Treatment Reviews</i> , 2005, 31, 456-473.	3.4	442
91	The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. <i>European Journal of Cancer</i> , 2005, 41, 1678-1689.	1.3	42
92	Growth factors and their relationship to neoplastic and paraneoplastic disease. <i>European Journal of Internal Medicine</i> , 2005, 16, 83-94.	1.0	3
93	Beneficial Effect of Rituximab in Combination with Oral Cyclophosphamide in Primary Chronic Cold Agglutinin Disease. <i>International Journal of Hematology</i> , 2005, 81, 421-423.	0.7	9
94	Cetuximab in Previously Treated Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2005, 5, S28-S33.	1.0	9
95	Treatment for Pancreatic Cancer: Current Therapy and Continued Progress. <i>Gastroenterology</i> , 2005, 128, 1642-1654.	0.6	142
96	Radio-immunotherapy in low-grade non-Hodgkin's lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2005, 18, 81-95.	0.7	13
97	Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. <i>Lung Cancer</i> , 2005, 49, 225-231.	0.9	48
98	Long term follow up and analysis of long term survivors in patients treated with paclitaxel-based concurrent chemo/radiation therapy for locally advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 50, 235-245.	0.9	14

#	ARTICLE	IF	CITATIONS
100	Pegfilgrastim. American Journal of Cancer, 2005, 4, 255-274.	0.4	1
101	Overexpression of polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology, 2005, 5, 259-265.	0.5	57
102	Exploring the Links Between Systemic Lupus Erythematosus and Cancer. Rheumatic Disease Clinics of North America, 2005, 31, 387-402.	0.8	27
103	Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Research, 2005, 7, R570-9.	2.2	112
104	Cutaneous lupus erythematosus: Understanding of clinical features, genetic basis, and pathobiology of disease guides therapeutic strategies. Autoimmunity, 2006, 39, 433-444.	1.2	72
106	Progestagens and Corticosteroids in the Management Cancer Cachexia. , 2006, , 653-666.		0
107	Diagnostic Imaging Modalities for Assessment of Lymphoma with Special Emphasis on CT, MRI, and Ultrasound. PET Clinics, 2006, 1, 219-230.	1.5	5
108	Aberrant Wnt/ β -Catenin Signaling in Pancreatic Adenocarcinoma. Neoplasia, 2006, 8, 279-289.	2.3	184
109	The place of targeted therapies in the management of non-small cell bronchial carcinoma. Revue Des Maladies Respiratoires, 2006, 23, 137-147.	1.7	2
110	Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas. BioDrugs, 2006, 20, 13-23.	2.2	24
111	Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma, 2006, 47, 1813-1817.	0.6	22
112	Early treatment with rhIL-11 in heavily pretreated patients with gynecologic cancer. Community Oncology, 2006, 3, 357-362.	0.2	1
113	A Rare Case of Combined Smallâ€Cell Lung Cancer with Unusual Soft Tissue Metastasis. Kaohsiung Journal of Medical Sciences, 2006, 22, 352-356.	0.8	9
114	New Therapies for Systemic Lupus Erythematosus: Cellular Targets. Rheumatic Disease Clinics of North America, 2006, 32, 201-215.	0.8	16
115	A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer. Journal of Molecular Diagnostics, 2006, 8, 335-341.	1.2	178
116	Role of Panitumumab in the Management of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 118-124.	1.0	34
117	Activity of Rituximab Monotherapy in Refractory Splenic Marginal Zone Lymphoma Complicated with Autoimmune Hemolytic Anemia. Clinical Lymphoma and Myeloma, 2006, 6, 496-499.	1.4	23
119	Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treatment Reviews, 2006, 32, 74-89.	3.4	157

#	ARTICLE	IF	CITATIONS
120	Epidermal Growth Factor Receptor-Targeted Agents for Lung Cancer. <i>Cancer Control</i> , 2006, 13, 129-140.	0.7	22
121	Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. <i>Anti-Cancer Drugs</i> , 2006, 17, 783-795.	0.7	51
122	Rituximab but not Other anti-CD20 Antibodies Reverses Multidrug Resistance in 2 B lymphoma Cell Lines, Blocks the Activity of P-glycoprotein (P-gp), and Induces P-gp to Translocate out of Lipid Rafts. <i>Journal of Immunotherapy</i> , 2006, 29, 536-544.	1.2	23
123	The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. <i>Radiation Oncology</i> , 2006, 1, 11.	1.2	154
124	Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. <i>British Journal of Cancer</i> , 2006, 94, 85-92.	2.9	64
125	Suppression of EGFR expression by antisense or small interference RNA inhibits U251 glioma cell growth in vitro and in vivo. <i>Cancer Gene Therapy</i> , 2006, 13, 530-538.	2.2	87
126	The CD20/CD20 suicide system: novel vectors with improved safety and expression profiles and efficient elimination of CD20-transgenic T cells. <i>Gene Therapy</i> , 2006, 13, 789-797.	2.3	30
127	Dysregulation of growth factor signaling in human hepatocellular carcinoma. <i>Oncogene</i> , 2006, 25, 3787-3800.	2.6	367
128	Targeting survivin via PI3K but not c-akt/PKB by anticancer drugs in immature neutrophils. <i>Oncogene</i> , 2006, 25, 6915-6923.	2.6	24
129	Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC). <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 221-230.	2.0	17
130	Radioimmunotherapy in a radiation oncology environment: Building a multi-specialty team. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, S4-S6.	0.4	1
131	EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. <i>Breast Cancer Research and Treatment</i> , 2006, 95, 211-218.	1.1	209
132	Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2006, 448, 797-804.	1.4	69
133	Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 419-426.	1.1	5
135	Steroid Receptors and Their Role in the Biology and Control of Breast Cancer Growth. <i>Seminars in Oncology</i> , 2006, 33, 631-641.	0.8	66
136	Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol. <i>BMC Cancer</i> , 2006, 6, 133.	1.1	78
137	Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance. <i>BMC Cancer</i> , 2006, 6, 150.	1.1	20
138	A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. <i>BMC Cancer</i> , 2006, 6, 285.	1.1	103

#	ARTICLE	IF	CITATIONS
139	Development of antibody-based therapeutics for oncology indications. <i>Drug Development Research</i> , 2006, 67, 699-728.	1.4	3
140	Induction of tubulin by docetaxel is associated with p53 status in human non small cell lung cancer cell lines. <i>International Journal of Cancer</i> , 2006, 118, 317-325.	2.3	21
141	The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary. <i>Cancer Biology and Therapy</i> , 2006, 5, 1136-1141.	1.5	63
142	A Novel Methionine Aminopeptidase-2 Inhibitor, PPI-2458, Inhibits Non-Hodgkin's Lymphoma Cell Proliferation In vitro and In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 2583-2590.	3.2	18
143	Trichloroethylene Cancer Epidemiology: A Consideration of Select Issues. <i>Environmental Health Perspectives</i> , 2006, 114, 1471-1478.	2.8	80
144	Hematopoietic Support With Moderately Myelosuppressive Chemotherapy Regimens: A Nursing Perspective. <i>Clinical Journal of Oncology Nursing</i> , 2006, 10, 383-388.	0.3	8
145	Key Scientific Issues in the Health Risk Assessment of Trichloroethylene. <i>Environmental Health Perspectives</i> , 2006, 114, 1445-1449.	2.8	71
146	The epidermal growth factor family has a dual role in deciding the fate of cancer cells. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2006, 66, 623-630.	0.6	10
147	Peroxisome Proliferator-Activated Receptor β Is Highly Expressed in Pancreatic Cancer and Is Associated With Shorter Overall Survival Times. <i>Clinical Cancer Research</i> , 2006, 12, 6444-6451.	3.2	54
148	Magnitude of Stromal Hemangiogenesis Correlates with Histologic Subtype of Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2006, 12, 5622-5631.	3.2	76
149	Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 2676-2684.	1.9	216
150	Cetuximab and Irinotecan Interact Synergistically to Inhibit the Growth of Orthotopic Anaplastic Thyroid Carcinoma Xenografts in Nude Mice. <i>Clinical Cancer Research</i> , 2006, 12, 600-607.	3.2	91
151	Fluorodeoxyuridine Modulates Cellular Expression of the DNA Base Excision Repair Enzyme Uracil-DNA Glycosylase. <i>Cancer Research</i> , 2006, 66, 8829-8837.	0.4	39
153	Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer. <i>British Journal of Cancer</i> , 2006, 94, 1927-1935.	2.9	76
154	Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab. <i>Clinical Cancer Research</i> , 2007, 13, 2392-2399.	3.2	55
155	Treatment Approaches and Nursing Applications for Non-Hodgkin Lymphoma. <i>Clinical Journal of Oncology Nursing</i> , 2007, 11, 13-21.	0.3	2
156	A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects. <i>Oncologist</i> , 2007, 12, 1084-1095.	1.9	144
157	Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2007, 13, 523-531.	3.2	23

#	ARTICLE	IF	CITATIONS
158	Nuclear Expression of Phosphorylated EGFR Is Associated with Poor Prognosis of Patients with Esophageal Squamous Cell Carcinoma. <i>Pathobiology</i> , 2007, 74, 15-21.	1.9	83
159	Erlotinib in cancer treatment. <i>Annals of Oncology</i> , 2007, 18, vi35-vi41.	0.6	111
160	Modeling Breast Cancer-associated c-Src and EGFR Overexpression in Human MECs: c-Src and EGFR Cooperatively Promote Aberrant Three-dimensional Acinar Structure and Invasive Behavior. <i>Cancer Research</i> , 2007, 67, 4164-4172.	0.4	72
161	The Future of Anti-EGFR Therapy. <i>International Journal of Biological Markers</i> , 2007, 22, 88-93.	0.7	2
162	Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. <i>Anti-Cancer Drugs</i> , 2007, 18, 7-15.	0.7	120
163	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2007, 2, 22-28.	0.5	71
164	Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. <i>Nuclear Medicine and Biology</i> , 2007, 34, 55-70.	0.3	67
165	Cetuximab combined with radiotherapy: An alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?. <i>European Journal of Cancer</i> , 2007, 43, 35-45.	1.3	66
166	EGFR gene and protein expression in breast cancers. <i>European Journal of Surgical Oncology</i> , 2007, 33, 956-960.	0.5	37
167	Apoptosis, Senescence, and Cancer. , 2007, , .		8
168	Hodgkin's and Non-Hodgkin's Lymphomas. <i>Radiologic Clinics of North America</i> , 2007, 45, 69-83.	0.9	29
169	Biologics in General Medicine. , 2007, , .		1
170	Monoclonal Antibody Targeted Radiation Cancer Therapy. , 2007, , 50-58.		0
171	A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective. <i>Journal of Medical Economics</i> , 2007, 10, 255-271.	1.0	10
172	Targeting B Lymphocytes as Therapy for ANCA-Associated Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2007, 33, 741-754.	0.8	12
174	Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. <i>Lung Cancer</i> , 2007, 56, 383-389.	0.9	131
175	Synthesis and biological evaluation of 3-(azolylmethyl)-1H-indoles and 3-(1±-azolybenzyl)-1H-indoles as selective aromatase inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2007, 22, 667-676.	2.5	8
176	Rapidly Fatal <i>Acanthamoeba</i> Encephalitis and Treatment of Cryoglobulinemia. <i>Emerging Infectious Diseases</i> , 2007, 13, 469-471.	2.0	31

#	ARTICLE	IF	CITATIONS
177	Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 397-404.	0.4	22
178	Gene Expression Profiles as Markers of Aggressive Disease—EGFR as a Factor. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S102-S105.	0.4	7
179	Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. <i>Oncogene</i> , 2007, 26, 3704-3713.	2.6	93
180	A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. <i>Leukemia</i> , 2007, 21, 1405-1412.	3.3	28
181	High expression of RelA/p65 is associated with activation of nuclear factor- κ B-dependent signaling in pancreatic cancer and marks a patient population with poor prognosis. <i>British Journal of Cancer</i> , 2007, 97, 523-530.	2.9	135
182	The Prognostic Significance of Epidermal Growth Factor Receptor Expression in Clear-Cell Renal Cell Carcinoma: A Call for Standardized Methods for Immunohistochemical Evaluation. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 264-270.	0.9	26
183	High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: A TMA-based immunohistochemical analysis. <i>Oral Oncology</i> , 2007, 43, 193-198.	0.8	115
184	Quantitative PET of EGFR expression in xenograft-bearing mice using ^{64}Cu -labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 850-858.	3.3	231
185	Pharmacophore mapping of flavone derivatives for aromatase inhibition. <i>Molecular Diversity</i> , 2008, 12, 65-76.	2.1	18
186	Non-Invasive PET Imaging of EGFR Degradation Induced by a Heat Shock Protein 90 Inhibitor. <i>Molecular Imaging and Biology</i> , 2008, 10, 99-106.	1.3	41
187	ErbB4/HER4: Role in Mammary Gland Development, Differentiation and Growth Inhibition. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2008, 13, 235-246.	1.0	85
188	Multimodality imaging of the HER-kinase axis in cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 186-208.	3.3	109
189	Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 1413-1420.	3.3	11
190	Current aspects of targeted therapy in head and neck tumors. <i>European Archives of Oto-Rhino-Laryngology</i> , 2008, 265, 3-12.	0.8	38
191	Preoperative evaluation of pancreatic adenocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Surgery</i> , 2008, 15, 429-435.	2.0	46
192	Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. <i>Cancer</i> , 2008, 112, 2710-2719.	2.0	189
193	Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 202-212.	1.2	34
194	Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. <i>Head and Neck</i> , 2008, 30, 667-674.	0.9	50

#	ARTICLE	IF	CITATIONS
195	Why Rituximab Works. <i>Journal of Investigative Dermatology</i> , 2008, 128, 2744.	0.3	1
196	Modifying Effects of IL6 Polymorphisms on Body Size-Associated Breast Cancer Risk. <i>Obesity</i> , 2008, 16, 339-347.	1.5	39
197	Aromatase inhibitors in ovarian cancer: is there a role?. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 600-614.	1.2	42
198	Absence of epidermal growth factor receptor mutations in cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 749-754.	1.2	33
199	Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16. <i>British Journal of Haematology</i> , 2008, 140, 635-643.	1.2	115
200	Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. <i>British Journal of Haematology</i> , 2008, 143, 296-298.	1.2	31
201	Update on Molecular Diagnostic Tests in Head and Neck Cancer. <i>Seminars in Oncology</i> , 2008, 35, 198-210.	0.8	16
202	Estrogens participate in the antidepressant-like effect of desipramine and fluoxetine in male rats. <i>Pharmacology Biochemistry and Behavior</i> , 2008, 88, 332-340.	1.3	51
203	Association of K-ras Mutational Status and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Receiving Panitumumab Alone. <i>Clinical Colorectal Cancer</i> , 2008, 7, 184-190.	1.0	147
205	Imaging of Abdominal Lymphoma. <i>Radiologic Clinics of North America</i> , 2008, 46, 265-285.	0.9	41
206	Pharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of 188Re-DXR-liposome in C26 colon carcinoma ascites mice model. <i>Nuclear Medicine and Biology</i> , 2008, 35, 883-893.	0.3	41
207	The B cell in systemic lupus erythematous: a rational target for more effective therapy. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1374-1381.	0.5	17
208	Gefitinib in Advanced Non-Small Cell Lung Cancer: Does It Deserve a Second Chance?. <i>Oncologist</i> , 2008, 13, 933-944.	1.9	40
209	Development of monoclonal antibodies for the treatment of colorectal cancer. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, S3-S7.	0.5	23
210	Sequential Therapy With Tamoxifen and Aromatase Inhibitors in Early-Stage Postmenopausal Breast Cancer: A Review of the Evidence. <i>Oncology Nursing Forum</i> , 2008, 35, 714-721.	0.5	2
211	RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR. <i>Cancer Research</i> , 2008, 68, 4183-4191.	0.4	84
212	<i>Pharmacology and Pharmacotherapy</i> , 2008, , 65-203.		1
213	Synergistic cytotoxicity of Bcl-xL inhibitor, gossypol and chemotherapeutic agents in non-Hodgkin's lymphoma cells. <i>Cancer Biology and Therapy</i> , 2008, 7, 51-60.	1.5	20

#	ARTICLE	IF	CITATIONS
214	Neuregulin-1: A Potential Endogenous Protector in Perinatal Brain White Matter Damage. <i>Neonatology</i> , 2008, 93, 182-187.	0.9	29
215	A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers. <i>British Journal of Cancer</i> , 2008, 98, 1774-1780.	2.9	47
216	Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development. <i>British Journal of Cancer</i> , 2008, 98, 900-906.	2.9	22
217	MS4A12 Is a Colon-Selective Store-Operated Calcium Channel Promoting Malignant Cell Processes. <i>Cancer Research</i> , 2008, 68, 3458-3466.	0.4	58
218	The Potency of Erythropoietin-Mimic Antibodies Correlates Inversely with Affinity. <i>Journal of Immunology</i> , 2008, 181, 1282-1287.	0.4	26
219	GM-CSF plus rituximab immunotherapy: Translation of biologic mechanisms into therapy for indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2008, 49, 1681-1692.	0.6	19
220	A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2008, 19, 332-339.	0.6	28
221	Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 737-740.	0.2	30
222	NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. <i>Cell Cycle</i> , 2008, 7, 81-88.	1.3	48
223	Epidermal Growth Factor Receptor-Related Tumor Markers and Clinical Outcomes with Erlotinib in Non-small Cell Lung Cancer: An Analysis of Patients from German Centers in the TRUST Study. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1446-1453.	0.5	97
224	The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. <i>Blood</i> , 2008, 112, 711-720.	0.6	97
225	Biological Agents in Non-small Cell Lung Cancer: A Review of Recent Advances and Clinical Results with a Focus on Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor. <i>Journal of Thoracic Oncology</i> , 2008, 3, 664-673.	0.5	35
226	Clinico-Pathologic and Biologic Predictors of EGFR Inhibitors Activity and Efficacy in Lung and in Colorectal Cancer. <i>Current Signal Transduction Therapy</i> , 2008, 3, 234-243.	0.3	0
227	Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities. <i>Current Pharmaceutical Design</i> , 2008, 14, 2983-2998.	0.9	77
228	Targeting Breast Cancer. <i>Nurse Practitioner</i> , 2008, 33, 16-22.	0.2	0
229	New directions in the management of advanced pancreatic cancer: a review. <i>Anti-Cancer Drugs</i> , 2008, 19, 435-446.	0.7	36
230	Targeting Breast Cancer. <i>Nurse Practitioner</i> , 2008, 33, 22-23.	0.2	2
231	Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44. <i>Chinese Medical Journal</i> , 2008, 121, 1702-1706.	0.9	3

#	ARTICLE	IF	CITATIONS
232	Small molecule tyrosine kinase inhibitors in pancreatic cancer. <i>Biologics: Targets and Therapy</i> , 2008, 2, 707.	3.0	17
233	Role of STAT3 as a Negative Regulator in Mac2- Binding Protein Expression. <i>Annals of Laboratory Medicine</i> , 2008, 28, 230-238.	1.2	2
234	Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model. <i>Biologics: Targets and Therapy</i> , 2008, , 27.	3.0	3
235	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. <i>Biologics: Targets and Therapy</i> , 0, , 215.	3.0	12
236	Update on the rational use of tositumomab and iodine-131 tositumomab radioimmunotherapy for the treatment of non-Hodgkin's lymphoma. <i>OncoTargets and Therapy</i> , 2009, 2, 229.	1.0	4
237	Effect of aromatase inhibitor (fadrozole) on proliferation, estradiol production and telomerase activity in pig granulosa cells in vitro. <i>Czech Journal of Animal Science</i> , 2009, 54, 566-574.	0.5	4
238	Immunohistochemical expression of HER-2/NEU-CERBB-2 in patients with adenocarcinoma of the stomach. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2009, 36, 131-134.	0.3	5
239	Safety and efficacy study of the recombinant granulocyte colony-stimulating factor for prevention of neutropenia and neutropenia-related complications in women with metastatic breast cancer receiving docetaxel/doxorubicin. <i>Medicina (Lithuania)</i> , 2009, 45, 600.	0.8	2
240	The Complex Relationship between BRCA1 and ER β in Hereditary Breast Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 1514-1518.	3.2	58
241	Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis. <i>Oncology</i> , 2009, 77, 124-133.	0.9	61
242	Current Treatments for Advanced Stage Non-Small Cell Lung Cancer. <i>Proceedings of the American Thoracic Society</i> , 2009, 6, 233-241.	3.5	130
243	Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?. <i>Molecular Cancer Research</i> , 2009, 7, 1000-1012.	1.5	116
244	Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non-small cell Lung Cancer Cell Lines with MET Amplification. <i>Clinical Cancer Research</i> , 2009, 15, 907-913.	3.2	47
245	Stat1 is an inhibitor of Ras-MAPK signaling and Rho small GTPase expression with implications in the transcriptional signature of Ras transformed cells. <i>Cell Cycle</i> , 2009, 8, 2070-2079.	1.3	24
246	Aromatase Inhibitors to Augment Height: Continued Caution and Study Required. <i>JCRPE Journal of Clinical Research in Pediatric Endocrinology</i> , 2009, 1, 256-261.	0.4	21
247	Oncocytic, focally anaplastic, thyroid cancer responding to erlotinib. <i>Journal of Oncology Pharmacy Practice</i> , 2009, 15, 111-117.	0.5	24
248	Role of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer. <i>Annals of Oncology</i> , 2009, 20, 615-620.	0.6	61
249	Vitamin D and Non-Hodgkin Lymphoma Risk in Adults: A Review. <i>Cancer Investigation</i> , 2009, 27, 942-951.	0.6	17

#	ARTICLE	IF	CITATIONS
250	Strategies for Molecular Imaging of Epidermal Growth Factor Receptor Tyrosine Kinase in Cancer. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1199-1202.	2.8	49
251	Neuroendocrine Carcinomas of the Lung. <i>American Journal of Clinical Pathology</i> , 2009, 131, 206-221.	0.4	74
252	Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions. <i>Clinical Cancer Research</i> , 2009, 15, 6582-6594.	3.2	59
253	Dose-Dependent Increases in Circulating TGF- β and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent. <i>Clinical Cancer Research</i> , 2009, 15, 2397-2405.	3.2	38
254	Testosterone reduces cumulative burying in female Wistar rats with minimal participation of estradiol. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 93, 406-412.	1.3	11
255	Adjuvant endocrine therapy for perimenopausal women with early breast cancer. <i>Breast</i> , 2009, 18, 2-7.	0.9	14
256	Rituximab-associated acute thrombocytopenia: An underdiagnosed phenomenon. <i>American Journal of Hematology</i> , 2009, 84, 247-250.	2.0	59
257	The combination of berberine and irradiation enhances anti-cancer effects via activation of p38 MAPK pathway and ROS generation in human hepatoma cells. <i>Journal of Cellular Biochemistry</i> , 2009, 107, 955-964.	1.2	87
258	Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 170-179.	2.0	42
259	Expression and significance of EGFR in malignant peripheral nerve sheath tumor. <i>Journal of Neuro-Oncology</i> , 2009, 94, 383-388.	1.4	32
260	Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1017-1022.	1.1	44
261	Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). <i>BMC Medical Physics</i> , 2009, 9, 1.	2.4	174
262	Long-term safety of biologics in dermatology. <i>Dermatologic Therapy</i> , 2009, 22, 2-21.	0.8	13
263	Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells. <i>Innate Immunity</i> , 2009, 15, 91-100.	1.1	60
264	Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2009, 63, 1-9.	0.9	38
265	Refinement of the Population Pharmacokinetic Model for the Monoclonal Antibody Matuzumab. <i>Clinical Pharmacokinetics</i> , 2009, 48, 477-487.	1.6	8
266	A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Visceral Metastases. <i>Clinical Breast Cancer</i> , 2009, 9, 39-44.	1.1	40
267	KRAS Testing in Metastatic Colorectal Cancer: Implications on the Use of Biologic Agents. <i>Clinical Colorectal Cancer</i> , 2009, 8, 135-140.	1.0	4

#	ARTICLE	IF	CITATIONS
269	The late adverse events of rituximab therapy â€“ rare but there!. <i>Leukemia and Lymphoma</i> , 2009, 50, 1083-1095.	0.6	116
270	A Stem Cellâ€“Based Platform for the Discovery and Development of Antitumor Therapeutic Antibodies to Novel Targets. , 0, , 313-335.		2
271	Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers. <i>Current Pharmaceutical Design</i> , 2009, 15, 758-776.	0.9	57
272	Yeast-Derived β-Glucan in Combination with Anti-Tumor Monoclonal Antibody Therapy in Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2009, 4, 101-109.	0.8	12
273	Molecular Targeted Therapy of Biliary Tract Cancer â€“ Results of the First Clinical Studies. <i>Current Drug Targets</i> , 2010, 11, 834-850.	1.0	36
274	Recent Development of Molecular-Targeted Drugs in Lung Cancer. <i>Internal Medicine</i> , 2010, 49, 1923-1934.	0.3	6
275	Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 59.	1.0	1
276	Effects of chemotherapy-induced neutropenia on quality of life. <i>Cancer Nursing Practice</i> , 2010, 9, 30-33.	0.2	3
277	A biomathematical model of human thrombopoiesis under chemotherapy. <i>Journal of Theoretical Biology</i> , 2010, 264, 287-300.	0.8	25
278	Guidelines for safety management of granulocyte transfusion in Japan. <i>International Journal of Hematology</i> , 2010, 91, 201-208.	0.7	9
279	Overexpression and activation of epidermal growth factor receptor in hemangioblastomas. <i>Journal of Neuro-Oncology</i> , 2010, 99, 195-200.	1.4	17
280	Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidneyâ€™Transplant Patients. <i>American Journal of Transplantation</i> , 2010, 10, 89-98.	2.6	164
281	Effects of propranolol in combination with radiation on apoptosis and survival of gastric cancer cells in vitro. <i>Radiation Oncology</i> , 2010, 5, 98.	1.2	39
282	Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. <i>British Journal of Haematology</i> , 2010, 149, 334-351.	1.2	88
283	RNAi-mediated knockdown of AURKB and EGFR shows enhanced therapeutic efficacy in prostate tumor regression. <i>Gene Therapy</i> , 2010, 17, 352-359.	2.3	42
284	Role of rituximab in first-line treatment of chronic lymphocytic leukemia. <i>Therapeutics and Clinical Risk Management</i> , 2010, 7, 1.	0.9	8
285	Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2010, 5, e12702.	1.1	128
286	Neuroendocrine Tumors of the Lung. , 2010, , 137-164.		1

#	ARTICLE	IF	CITATIONS
287	HemoHIM Enhances the Therapeutic Efficacy of Ionizing Radiation Treatment in Tumor-Bearing Mice. <i>Journal of Medicinal Food</i> , 2010, 13, 47-53.	0.8	10
288	Cost-Effectiveness of Erlotinib versus Docetaxel for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in the United Kingdom. <i>Journal of International Medical Research</i> , 2010, 38, 9-21.	0.4	41
289	Non-Hodgkin's lymphoma: Is India ready to incorporate recent advances in day to day practice?. <i>Journal of Cancer Research and Therapeutics</i> , 2010, 6, 36.	0.3	8
290	Role of Phytoestrogens in Cancer Therapy. <i>Planta Medica</i> , 2010, 76, 1132-1142.	0.7	71
291	Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. <i>Translational Research</i> , 2010, 156, 98-105.	2.2	27
292	Role of Antibodies in Cancer Treatment (An Overview). , 2010, , 135-152.		3
293	Infusion Reactions. <i>Clinical Journal of Oncology Nursing</i> , 2010, 14, E10-E21.	0.3	165
294	Expression of bcl-2 correlates with poor prognosis and modulates migration of nasopharyngeal carcinoma cells. <i>Clinica Chimica Acta</i> , 2010, 411, 400-405.	0.5	19
295	Computer-aided structure analysis of an epimerized dehydroepiandrosterone derivative and its biological effect in a model of reactive gliosis. <i>Steroids</i> , 2010, 75, 265-271.	0.8	2
296	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 221-232.	13.9	2,275
297	Low-Dose Metronomic Paclitaxel Chemotherapy Suppresses Breast Tumors and Metastases in Mice. <i>Cancer Investigation</i> , 2010, 28, 74-84.	0.6	47
298	Concurrent cetuximab and radiotherapy after docetaxel+cisplatin induction chemotherapy in stage III NSCLC: Satellite's A phase II study from the Swedish Lung Cancer Study Group. <i>Lung Cancer</i> , 2011, 71, 166-172.	0.9	51
299	Pharmacokinetics and Pharmacodynamics of Pegfilgrastim. <i>Clinical Pharmacokinetics</i> , 2011, 50, 295-306.	1.6	122
300	Master Techniques in Blepharoplasty and Periorbital Rejuvenation. , 2011, , .		8
301	MicroRNA and Cancer. <i>Methods in Molecular Biology</i> , 2011, , .	0.4	8
302	MicroRNA Regulation of Growth Factor Receptor Signaling in Human Cancer Cells. <i>Methods in Molecular Biology</i> , 2011, 676, 147-163.	0.4	38
304	Hemofilia adquirida tratada con anti CD20, un anticuerpo anti linfocito B. <i>Revista Medica De Chile</i> , 2011, 139, 357-361.	0.1	2
305	Advances in Fine Needle Aspiration Cytology for the Diagnosis of Pulmonary Carcinoma. <i>Pathology Research International</i> , 2011, 2011, 1-7.	1.4	33

#	ARTICLE	IF	CITATIONS
306	An Open-Label Multicenter Safety, Tolerability, and Efficacy Study of Recombinant Granulocyte Colony-Stimulating Factor in the Prevention of Neutropenic Complications in Breast Cancer Patients. <i>Medicina (Lithuania)</i> , 2011, 47, 428.	0.8	4
307	From Clinical Trials to Clinical Practice: Predictors of Response to Erlotinib in Advanced Non-Small Cell Lung Cancer Patients Pretreated with Chemotherapy. <i>Tumori</i> , 2011, 97, 160-165.	0.6	10
308	HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2011, 6, e18087.	1.1	84
309	Versican G3 Domain Modulates Breast Cancer Cell Apoptosis: A Mechanism for Breast Cancer Cell Response to Chemotherapy and EGFR Therapy. <i>PLoS ONE</i> , 2011, 6, e26396.	1.1	29
310	Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1849-1856.	0.5	121
311	Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1086-1113.	2.3	29
312	Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 563-571.	2.3	0
313	Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. <i>Cancer Science</i> , 2011, 102, 425-431.	1.7	51
314	HGF-independent potentiation of EGFR action by c-Met. <i>Oncogene</i> , 2011, 30, 3625-3635.	2.6	95
315	Adaptive immunity in rheumatic diseases – “Bystander or pathogenic player?”. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 785-800.	1.4	5
316	Tumor treating fields: concept, evidence and future. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1099-1106.	1.9	70
317	Protein-based tumor molecular imaging probes. <i>Amino Acids</i> , 2011, 41, 1013-1036.	1.2	12
318	Examination of the use of Exemestane in patients with metastatic breast cancer. <i>Breast Cancer</i> , 2011, 18, 189-194.	1.3	1
319	Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. <i>Targeted Oncology</i> , 2011, 6, 171-180.	1.7	13
320	Site-specific modification of ED-B-targeting antibody using intein-fusion technology. <i>BMC Biotechnology</i> , 2011, 11, 76.	1.7	30
321	Screening for ligands of human aromatase from mulberry (<i>Mori alba L.</i>) leaf by using high-performance liquid chromatography/tandem mass spectrometry. <i>Food Chemistry</i> , 2011, 126, 1337-1343.	4.2	19
322	Pharmacologie et pharmacoth�rapie. , 2011, , 65-209.		0
323	Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. <i>British Journal of Radiology</i> , 2011, 84, S168-S178.	1.0	2

#	ARTICLE	IF	CITATIONS
324	Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing. <i>Journal of Thoracic Oncology</i> , 2011, 6, 451-458.	0.5	230
325	Focal Rituximab-Induced Edematous Reaction at Primary Cutaneous Follicle Center Lymphoma Lesions: Case Report and Literature Review. <i>Dermatology</i> , 2011, 223, 200-202.	0.9	12
326	The Prognostic Significance of the Serum p53 Protein Concentration in Chinese Patients with Non-Hodgkin Lymphoma. <i>Turkish Journal of Haematology</i> , 2012, 29, 376-384.	0.2	3
327	Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. <i>Pharmacogenomics Journal</i> , 2012, 12, 10-21.	0.9	50
328	Nuclear EGFR Suppresses Ribonuclease Activity of Polynucleotide Phosphorylase through DNAPK-mediated Phosphorylation at Serine 776. <i>Journal of Biological Chemistry</i> , 2012, 287, 31015-31026.	1.6	43
329	Cigarette-Smoke-Induced Dysregulation of MicroRNA Expression and Its Role in Lung Carcinogenesis. <i>Pulmonary Medicine</i> , 2012, 2012, 1-9.	0.5	33
330	MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 154-164.	1.9	121
331	Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. <i>Current Opinion in Rheumatology</i> , 2012, 24, 15-23.	2.0	43
332	Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. <i>Oncology Reports</i> , 2012, 27, 923-928.	1.2	11
333	Targeting the Epidermal Growth Factor Receptor in Glioblastoma Treatment. <i>Current Signal Transduction Therapy</i> , 2012, 7, 3-13.	0.3	0
334	Fluorescent Dye Conjugates for Optical Imaging of Cancer. , 2012, , 451-482.		0
335	Novel human monoclonal antibody against epidermal growth factor receptor as an imaging probe for hepatocellular carcinoma. <i>Nuclear Medicine Communications</i> , 2012, 33, 719-725.	0.5	6
336	<i>Bordetella holmesii</i> bacteremia in a renal transplant recipient: emergence of a new pathogen. <i>Transplant Infectious Disease</i> , 2012, 14, E134-6.	0.7	7
337	Clinical use of biologics in vasculitis syndromes. <i>Biologics: Targets and Therapy</i> , 2012, 6, 371.	3.0	3
338	Immunotherapies in Dermatologic Disorders. <i>Medical Clinics of North America</i> , 2012, 96, 565-582.	1.1	7
339	Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1852-1860.	1.0	28
340	Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 1945-1948.	0.6	12
341	EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia. <i>Journal of Receptor and Signal Transduction Research</i> , 2012, 32, 142-149.	1.3	14

#	ARTICLE	IF	CITATIONS
342	Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. <i>British Journal of Pharmacology</i> , 2012, 166, 823-846.	2.7	62
343	Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice. <i>Immunology Letters</i> , 2012, 143, 44-52.	1.1	39
344	The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. <i>BMC Cancer</i> , 2012, 12, 583.	1.1	136
345	Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. <i>Molecular Cancer</i> , 2012, 11, 47.	7.9	27
346	Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer. <i>World Journal of Surgical Oncology</i> , 2012, 10, 77.	0.8	23
347	Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers. <i>Journal of Translational Medicine</i> , 2012, 10, 161.	1.8	32
348	Pharmacokinetic and -dynamic modelling of G-CSF derivatives in humans. <i>Theoretical Biology and Medical Modelling</i> , 2012, 9, 32.	2.1	32
349	Novel targeted agents for gastric cancer. <i>Journal of Hematology and Oncology</i> , 2012, 5, 31.	6.9	43
350	The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. <i>Annals of Epidemiology</i> , 2012, 22, 855-862.	0.9	19
351	The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. <i>Cancer Epidemiology</i> , 2012, 36, 490-496.	0.8	76
352	A Phase Ib, Dose-Finding Study of Erlotinib in Combination With a Fixed Dose of Pertuzumab in Patients With Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 432-441.	1.1	19
353	Are EUS and FNA and EBUS and TBNA specimens reliable for subtyping non-small cell lung cancer?. <i>Lung Cancer</i> , 2012, 76, 46-50.	0.9	26
356	Innovation in Esophageal Surgery. , 2012, , .		1
357	Correlation between radioactivity and chemotherapeutics of the ¹¹¹ In-VNB-liposome in pharmacokinetics and biodistribution in rats. <i>International Journal of Nanomedicine</i> , 2012, 7, 683.	3.3	3
358	CASE 77. , 2012, , .		0
359	Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab. <i>Clinical Medicine Insights Ear, Nose and Throat</i> , 2012, 5, CMENT.S5129.	1.5	17
360	The Peptide Derived from erbB2 Auto-Inhibitor Herstatin Shared in the Same Epitope and Function with Functional Antibody 2C4. <i>Molecular Biotechnology</i> , 2012, 51, 174-182.	1.3	2
361	Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1063-1069.	1.1	39

#	ARTICLE	IF	CITATIONS
362	Nanoparticles for improving cancer diagnosis. <i>Materials Science and Engineering Reports</i> , 2013, 74, 35-69.	14.8	94
363	Resistance to Immunotherapeutic Antibodies in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , .	0.1	2
364	Exploring the chemical space of aromatase inhibitors. <i>Molecular Diversity</i> , 2013, 17, 661-677.	2.1	28
365	Molecular Imaging in Oncology. <i>Recent Results in Cancer Research</i> , 2013, , .	1.8	6
366	Comparative effects of gamma and microwave irradiation on anticarcinogenic effect of red chili in colon and liver of male albino rats. <i>Comparative Clinical Pathology</i> , 2013, 22, 287-293.	0.3	0
367	Diagnostic Pathology of Pleuropulmonary Neoplasia. , 2013, , .		8
368	Hepatic arterial infusion but not systemic application of cetuximab in combination with oxaliplatin significantly reduces growth of CC531 colorectal rat liver metastases. <i>International Journal of Colorectal Disease</i> , 2013, 28, 555-562.	1.0	5
369	Gene Expression Profiles Can Predict Panitumumab Monotherapy Responsiveness in Human Tumor Xenograft Models. <i>Neoplasia</i> , 2013, 15, 125-132.	2.3	8
370	Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. <i>European Journal of Radiology</i> , 2013, 82, 2011-2017.	1.2	47
371	Derlin-1 Is Overexpressed in Non-Small Cell Lung Cancer and Promotes Cancer Cell Invasion via EGFR-ERK Mediated Up-Regulation of MMP-2 and MMP-9. <i>American Journal of Pathology</i> , 2013, 182, 954-964.	1.9	112
372	MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. <i>Scandinavian Journal of Urology</i> , 2013, 47, 423-432.	0.6	69
373	Cetuximab Response of Lung Cancer Derived EGF Receptor Mutants Is Associated with Asymmetric Dimerization. <i>Cancer Research</i> , 2013, 73, 6770-6779.	0.4	87
374	Pharmacokinetics, Pharmacodynamics and Physiologically-Based Pharmacokinetic Modelling of Monoclonal Antibodies. <i>Clinical Pharmacokinetics</i> , 2013, 52, 83-124.	1.6	191
375	Multifunctional Magnetic Resonance Imaging Probes. <i>Recent Results in Cancer Research</i> , 2013, 187, 151-190.	1.8	6
376	Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2013, 61, 25-41.	1.0	191
377	Multidisciplinary Management of Small Cell Lung Cancer. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 329-343.	0.6	13
378	Target-specific Tc(CO) ₃ -complexes for in vivo imaging. <i>Journal of Organometallic Chemistry</i> , 2013, 744, 125-139.	0.8	36
379	CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 925-933.	2.0	35

#	ARTICLE	IF	CITATIONS
380	Expression and clinical significance of apolipoprotein E in pancreatic ductal adenocarcinoma. <i>Medical Oncology</i> , 2013, 30, 583.	1.2	25
381	Isogenic human mammary epithelial cell lines: novel tools for target identification and validation. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 437-456.	1.1	3
382	Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. <i>Clinical and Experimental Metastasis</i> , 2013, 30, 447-455.	1.7	12
383	An Overview of Phenylcyclopropylamine Derivatives: Biochemical and Biological Significance and Recent Developments. <i>Medicinal Research Reviews</i> , 2013, 33, 873-910.	5.0	30
384	Microsatellite Instability and TARBP2 Mutation Study in Upper Urinary Tract Urothelial Carcinoma. <i>American Journal of Clinical Pathology</i> , 2013, 139, 765-770.	0.4	15
385	Combined Inhibition of HER1/EGFR and RAC1 Results in a Synergistic Antiproliferative Effect on Established and Primary Cultured Human Glioblastoma Cells. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1783-1795.	1.9	50
386	Regulation of Epidermal Growth Factor Receptor Signaling by plasmid-based MicroRNA-7 inhibits human malignant gliomas growth and metastasis in vivo. <i>Neoplasia</i> , 2013, 60, 274-283.	0.7	46
387	Radiobiologic Optimization of Combination Radiopharmaceutical Therapy Applied to Myeloablative Treatment of Non-Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1535-1542.	2.8	20
388	Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. <i>Theranostic Approaches to Improve Therapeutics. Pharmacological Reviews</i> , 2013, 65, 1214-1256.	7.1	42
389	The Role of Versican in Modulating Breast Cancer Cell Self-renewal. <i>Molecular Cancer Research</i> , 2013, 11, 443-455.	1.5	48
390	Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. <i>Blood</i> , 2013, 121, 4694-4702.	0.6	79
391	Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. <i>Blood</i> , 2013, 121, 5192-5202.	0.6	75
392	Predictive markers for the response to 5-fluorouracil therapy in cancer cells: Constant-field gel electrophoresis as a tool for prediction of response to 5-fluorouracil-based chemotherapy. <i>Oncology Letters</i> , 2013, 5, 321-327.	0.8	23
393	Evaluation of Novel Orthotopic Nude Mouse Models for Human Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 140-146.	0.5	25
394	Should new-onset arthralgia be considered a menopausal symptom?. <i>Menopause</i> , 2013, 20, 591-593.	0.8	6
395	Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2013, 6, 125.	1.0	36
396	Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors. <i>Molecular Cancer</i> , 2013, 12, 167.	7.9	37
397	Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 78-98.	2.3	331

#	ARTICLE	IF	CITATIONS
398	Psoriasis Induced by Trastuzumab (Herceptin®). <i>Annals of Dermatology</i> , 2013, 25, 229.	0.3	5
399	Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. <i>OncoTargets and Therapy</i> , 2013, 6, 427.	1.0	19
400	CA 125 concentration in portal blood as a predictor of resectability in pancreatic tumor. <i>Wspolczesna Onkologia</i> , 2013, 4, 394-399.	0.7	2
401	Applications of Nanosystems to Anticancer Drug Therapy (Part II. Dendrimers, Micelles, Lipid-based) <i>TJ ETQq1 1 0.784314 rgBT /Overlo</i>	0.8	29
402	Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action. <i>Oncology Reviews</i> , 2014, 8, 246.	0.8	42
403	Prognostic and predictive response factors in colorectal cancer patients: Between hope and reality. <i>World Journal of Gastroenterology</i> , 2014, 20, 15049.	1.4	74
404	Erlotinib in Glioblastoma – A Current Clinical Perspective. , 0, , .		1
405	Nedd4-1 is an exceptional prognostic biomarker for gastric cardia adenocarcinoma and functionally associated with metastasis. <i>Molecular Cancer</i> , 2014, 13, 248.	7.9	39
406	Modelling chemotherapy effects on granulopoiesis. <i>BMC Systems Biology</i> , 2014, 8, 138.	3.0	14
407	A novel role of the tumor size in pancreatic cancer as an ancillary factor for predicting resectability. <i>Journal of Cancer Research and Therapeutics</i> , 2014, 10, 142.	0.3	6
408	Multiple infusions of CD20-targeted T cells and low-dose IL-2 after SCT for high-risk non-Hodgkin's lymphoma: A pilot study. <i>Bone Marrow Transplantation</i> , 2014, 49, 73-79.	1.3	25
409	Prolonged progression-free survival and preserved quality of life in the Canadian prospective study of tositumomab and iodine-131-tositumomab for previously treated, rituximab-exposed, indolent non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2754-2760.	0.6	7
410	Does tumoral 111In-ibritumomab accumulation correlate with therapeutic effect and outcome in relapsed or refractory low-grade B-cell lymphoma patients undergoing 90Y-ibritumomab radioimmunotherapy?. <i>European Radiology</i> , 2014, 24, 3191-3198.	2.3	4
411	Effect of aromatase inhibitors on the endometrium and ovary with their possible role in ovulation in adult albino rats. <i>Egyptian Journal of Histology</i> , 2014, 37, 549-561.	0.0	0
412	Non-Hodgkin Lymphoma: Radioimmunotherapy Using Iodine-131 Labeled Murine Anti-CD20 Antibodies (131I-Tositumomab and Tositumomab, –Bexxar–). <i>Medical Radiology</i> , 2014, , 505-525.	0.0	0
413	Detection of Her-2/neu expression in gastric cancer: Quantitative PCR versus immunohistochemistry. <i>Experimental and Therapeutic Medicine</i> , 2014, 8, 1501-1507.	0.8	10
414	Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents. <i>Journal of Biological Inorganic Chemistry</i> , 2014, 19, 259-270.	1.1	21
415	Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2014, 6, 58-74.	1.2	8

#	ARTICLE	IF	CITATIONS
416	Pleckstrin homology domain leucine-rich repeat protein phosphatases set the amplitude of receptor tyrosine kinase output. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3957-65.	3.3	33
417	Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen. <i>Medical Oncology</i> , 2014, 31, 153.	1.2	1
418	Pretreatment with <i>Saccharomyces boulardii</i> does not prevent the experimental mucositis in Swiss mice. <i>Journal of Negative Results in BioMedicine</i> , 2014, 13, 6.	1.4	34
419	Surgery, wound healing, and metastasis: Recent insights and clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 16-26.	2.0	108
420	Treatment options in patients with metastatic gastric cancer: Current status and future perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 3905.	1.4	77
421	Chronopharmacology and Mechanism of Antitumor Effect of Erlotinib in Lewis Tumor-Bearing Mice. <i>PLoS ONE</i> , 2014, 9, e101720.	1.1	8
422	Practical experience with rituximab subcutaneous. <i>Cancer Nursing Practice</i> , 2015, 14, 29-37.	0.2	1
423	Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2-Metastatic Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2015, 9, BCBCR.S30771.	0.6	2
424	Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. <i>ImmunoTargets and Therapy</i> , 2015, 4, 173.	2.7	6
425	The pitfall of the transient, inconsistent anticancer capacity of antiestrogens and the mechanism of apparent antiestrogen resistance. <i>Drug Design, Development and Therapy</i> , 2015, 9, 4341.	2.0	14
426	Gastric metastasis from small cell lung cancer: A case report. <i>World Journal of Gastroenterology</i> , 2015, 21, 1684.	1.4	15
427	Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. <i>Oncotarget</i> , 2015, 6, 18162-18173.	0.8	90
428	Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2 ⁺ metastatic breast cancer: a retrospective chart review in community oncology practices in the US. <i>Current Medical Research and Opinion</i> , 2015, 31, 1095-1103.	0.9	9
429	Risk factors for late-onset neutropenia after rituximab treatment of B-cell lymphoma. <i>Hematology</i> , 2015, 20, 196-202.	0.7	16
430	Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 97-109.	1.1	13
431	Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma. , 2015, , 135-183.		0
433	A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study. <i>Annals of Oncology</i> , 2015, 26, 542-547.	0.6	96
434	Case studies on clinical evaluation of biosimilar monoclonal antibody: Scientific considerations for regulatory approval. <i>Biologicals</i> , 2015, 43, 1-10.	0.5	18

#	ARTICLE	IF	CITATIONS
435	Cross talk between the bombesin neuropeptide receptor and Sonic hedgehog pathways in small cell lung carcinoma. <i>Oncogene</i> , 2015, 34, 1679-1687.	2.6	31
436	A Role for Notch Signalling in Breast Cancer and Endocrine Resistance. <i>Stem Cells International</i> , 2016, 2016, 1-6.	1.2	50
437	Intraoperative fine needle aspirations - diagnosis and typing of lung cancer in small biopsies: challenges and limitations. <i>Diagnostic Pathology</i> , 2016, 11, 59.	0.9	18
438	An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 651-660.	1.7	14
439	Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas. <i>Molecular and Clinical Oncology</i> , 2016, 4, 467-471.	0.4	15
440	Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1971-1977.	2.8	15
441	SCLCâ€“State of the Art and What Does the Future Have in Store?. <i>Clinical Lung Cancer</i> , 2016, 17, 325-333.	1.1	48
442	miR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6. <i>Scientific Reports</i> , 2016, 6, 28968.	1.6	29
443	Biologics and Their Interactions with Radiation. , 2016, , 80-92.e4.		0
444	Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients. <i>Tumor Biology</i> , 2016, 37, 9089-9098.	0.8	20
445	Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions. <i>Drugs</i> , 2016, 76, 13-26.	4.9	11
446	Structure-based design of peptides against HER2 with cytotoxicity on colon cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2017, 45, 649-654.	1.9	3
447	Sexâ€“dependent effects of letrozole on anxiety in middleâ€“aged rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2017, 44, 93-98.	0.9	13
448	Simultaneous Interference with HER1/EGFR and RAC1 Signaling Drives Cytostasis and Suppression of Survivin in Human Glioma Cells in Vitro. <i>Neurochemical Research</i> , 2017, 42, 1543-1554.	1.6	10
449	Population pharmacokinetics of rituximab in patients with diffuse large Bâ€“cell lymphoma and association with clinical outcome. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1782-1790.	1.1	38
450	IFITM1 suppression blocks proliferation and invasion of aromatase inhibitor-resistant breast cancer inÂvivo by JAK/STAT-mediated induction of p21. <i>Cancer Letters</i> , 2017, 399, 29-43.	3.2	46
451	<scp>A</scp>ccuracy of cytology in sub typing non small cell lung carcinomas. <i>Diagnostic Cytopathology</i> , 2017, 45, 598-603.	0.5	15
452	Shikonin Inhibited Migration and Invasion of Human Lung Cancer Cells via Suppression of câ€“Metâ€“Mediated Epithelialâ€“toâ€“Mesenchymal Transition. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4639-4651.	1.2	44

#	ARTICLE	IF	CITATIONS
453	Migration of oral squamous cell carcinoma cells are induced by HGF/c-Met signalling via lamellipodia and filopodia formation. <i>Oncology Reports</i> , 2017, 37, 3674-3680.	1.2	15
454	DNA Mutations May Not Be the Cause of Cancer. <i>Oncology and Therapy</i> , 2017, 5, 85-101.	1.0	48
455	EGFR signaling pathways are wired differently in normal 184A1L5 human mammary epithelial and MDA-MB-231 breast cancer cells. <i>Journal of Cell Communication and Signaling</i> , 2017, 11, 341-356.	1.8	10
456	Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy. <i>Cancer Letters</i> , 2017, 388, 139-148.	3.2	54
457	Localized Urticaria During Rituximab Infusion for the Treatment of Cutaneous Lymphoid Hyperplasia. <i>Clinical Skin Cancer</i> , 2017, 2, 66-68.	0.1	1
458	Endoscopic ultrasonography can avoid unnecessary laparotomies in patients with pancreatic adenocarcinoma and undetected peritoneal carcinomatosis. <i>Pancreatology</i> , 2017, 17, 858-864.	0.5	6
459	The Antitumor Activity of IMG529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. <i>Neoplasia</i> , 2017, 19, 661-671.	2.3	29
460	Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney Transplant Recipients: Results From a Cohort in Germany. <i>Transplantation Proceedings</i> , 2017, 49, 2269-2273.	0.3	10
461	Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature. <i>Hematological Oncology</i> , 2017, 35, 591-598.	0.8	29
462	Predicting Adherence to Aromatase Inhibitor Therapy among Breast Cancer Survivors: An Application of the Protection Motivation Theory. <i>Breast Cancer: Basic and Clinical Research</i> , 2017, 11, 117822341769452.	0.6	23
463	Cardiac Immunomodulation. , 2017, , 681-714.		1
464	Oxidative Stress Gene Expression Profile Correlates with Cancer Patient Poor Prognosis: Identification of Crucial Pathways Might Select Novel Therapeutic Approaches. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-18.	1.9	102
465	SLE and Non-Hodgkin's Lymphoma: A Case Series and Review of the Literature. <i>Case Reports in Rheumatology</i> , 2017, 2017, 1-7.	0.2	10
466	NRF2 Regulates HER1 Signaling Pathway to Modulate the Sensitivity of Ovarian Cancer Cells to Lapatinib and Erlotinib. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-19.	1.9	20
467	Studies on non-steroidal inhibitors of aromatase enzyme; 4-(aryl/heteroaryl)-2-(pyrimidin-2-yl)thiazole derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1986-1995.	1.4	29
468	A flow cytometry-based assay to determine the phagocytic activity of both clinical and nonclinical antibody samples against <i>Chlamydia trachomatis</i> . <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 525-532.	1.1	14
469	The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells. <i>Molecular Cancer</i> , 2018, 17, 24.	7.9	54
470	The interplay of reactive oxygen species and the epidermal growth factor receptor in tumor progression and drug resistance. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 61.	3.5	103

#	ARTICLE	IF	CITATIONS
471	Receptor activities of persistent pollutant serum mixtures and breast cancer risk. <i>Endocrine-Related Cancer</i> , 2018, 25, 201-215.	1.6	11
472	Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 343-358.	1.2	8
473	PKG II effectively reversed EGF-induced protein expression alterations in human gastric cancer cell lines. <i>Cell Biology International</i> , 2018, 42, 435-442.	1.4	3
474	FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients. <i>Hematological Oncology</i> , 2018, 36, 299-306.	0.8	4
475	Normalized Serum EGF Levels as a Potential Biomarker in Non-Small Cell Lung Cancer: The Role of Platelets. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2018, 09, .	0.4	3
476	Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?. <i>Current Oncology Reports</i> , 2018, 20, 103.	1.8	9
477	Endocrine Therapy for Breast Cancer: A Model of Hormonal Manipulation. <i>Oncology and Therapy</i> , 2018, 6, 141-156.	1.0	30
478	NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1171-1182.	2.3	192
479	Fabrication of chitosan nanoparticles loaded with aromatase inhibitors for the advancement of gonadal development in <i>Clarias magur</i> (Hamilton, 1822). <i>Aquaculture</i> , 2018, 497, 125-133.	1.7	19
480	A tale of two antibodies: obinutuzumab versus rituximab. <i>British Journal of Haematology</i> , 2018, 182, 29-45.	1.2	123
481	Rituximab-induced Acute Thrombocytopenia in Granulomatosis with Polyangiitis. <i>Internal Medicine</i> , 2018, 57, 2247-2250.	0.3	7
482	Overcoming Resistance to PARP Inhibition. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2019, , 161-189.	0.1	0
484	Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials. <i>Frontiers in Oncology</i> , 2019, 9, 510.	1.3	49
486	Efficacy of repeat doses of avatrombopag: a case series. <i>Digestive Medicine Research</i> , 0, 2, 9-9.	0.2	4
487	ISOLATION OF CYTOTOXIC CONSTITUENT FROM BIOACTIVITY GUIDED FRACTION OF <i>ALYSICARPUS MONILIFER</i> L. (DC.). <i>International Journal of Pharmacy and Pharmaceutical Sciences</i> , 0, , 69-77.	0.3	1
488	Bullous pemphigoid. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 133-146.	0.5	132
489	Acupuncture and Vitamin D for the Management of Aromatase Inhibitor-Induced Arthralgia. <i>Current Oncology Reports</i> , 2019, 21, 51.	1.8	7
490	Pharmacotherapeutics and Molecular Mechanism of Phytochemicals in Alleviating Hormone-Responsive Breast Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-14.	1.9	14

#	ARTICLE	IF	CITATIONS
491	The lncRNA MIR2052HG regulates ER \pm levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. <i>Breast Cancer Research</i> , 2019, 21, 47.	2.2	36
492	Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1339-1348.	0.3	10
493	May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?. <i>Clinical Cancer Drugs</i> , 2019, 5, 75-86.	0.3	1
494	<p>Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobe on malignant lymphoma cells with CD20 overexpression</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 921-936.	3.3	22
495	⁶⁴Cu-based Radiopharmaceuticals in Molecular Imaging. <i>Technology in Cancer Research and Treatment</i> , 2019, 18, 153303381983075.	0.8	39
496	Assessment of the Aromatase Inhibitory Activity of Ma-Huang-Tang (MHT) and Its Active Compounds. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019, 2019, 1-9.	0.5	1
497	Novel Treatments for Advanced Cholangiocarcinoma. , 2019, , 227-243.		0
498	Cetuximab radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 257-263.	0.9	27
499	CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 521-532.	1.1	25
500	Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors. <i>Carcinogenesis</i> , 2019, 40, 998-1009.	1.3	20
501	Liver Cancers. , 2019, , .		2
502	A case of conjunctival MALT lymphoma: successfully treated with solely extended rituximab therapy. <i>International Ophthalmology</i> , 2019, 39, 687-691.	0.6	7
503	De Novo Colitis Associated With Rituximab in 21 Patients at a Tertiary Center. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 252-253.	2.4	37
504	Mucinous adenocarcinoma is a pharmacogenomically distinct subtype of colorectal cancer. <i>Pharmacogenomics Journal</i> , 2020, 20, 524-532.	0.9	30
505	Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 559596.	1.3	9
506	Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection. <i>Thoracic Cancer</i> , 2020, 11, 2782-2792.	0.8	15
507	Accuracy of breast MRI in patients receiving neoadjuvant endocrine therapy: comprehensive imaging analysis and correlation with clinical and pathological assessments. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 407-420.	1.1	11
508	Rituximab and eculizumab when treating nonmalignant hematologic disorders: infection risk, immunization recommendations, and antimicrobial prophylaxis needs. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 312-318.	0.9	12

#	ARTICLE	IF	CITATIONS
509	Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e201541.	2.8	26
510	Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 46-52.	0.6	13
511	De novo designing, assessment of target affinity and binding interactions against aromatase: Discovery of novel leads as anti-breast cancer agents. <i>Structural Chemistry</i> , 2021, 32, 847-858.	1.0	9
512	Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: A state-of-the-art review. <i>Drug Development Research</i> , 2021, 82, 309-340.	1.4	42